This Month in Psychopharmacology

THIS MONTH IN
PSYCHOPHARMACOLOGY

Browsing articles in "Eating Disorders"

Time Course of Relapse Following Acute Treatment for Anorexia Nervosa
August 13, 2021

Anorexia nervosa is a devastating eating disorder and determining a path to recovery is essential. In this study, the researchers sought to find the “point of rarity” -a point in remission in which the patient is unlikely to relapse in order to help determine at what point in remission a patient could be considered to be recovered. The study included...

Continue reading (Members only)

Medical Admissions Among Adolescents With Eating Disorders During the COVID-19 Pandemic
July 27, 2021

The COVID-19 pandemic has reportedly been associated with worsening symptoms of eating disorders in both adults and adolescents. In a recent study, a chart review of patients ages 10-23 admitted to a children’s hospital for restrictive eating disorders from March 2017 to March 2021 was conducted. Eating disorder-related medical admissions at the hospital increased significantly during the...

Continue reading (Members only)

Genetic And Phenotypic Assessments May Inform Early Diagnoses Of Eating Disorder
January 18, 2021

Eating disorders are common and disabling psychiatric disorders that emerge in late adolescence. The current study identified risk factors and correlates of subclinical disordered eating behaviors (DEBs) in adolescents for the purpose of informing early detection and targeted interventions. A multicenter prospective...

Continue reading (Members only)

FDA Warns of Possible Increased Risk of Cancer With Lorcaserin
January 30, 2020

In 2016, the World Health Organization reported that more than 1.9 billion adults were overweight and of these over 650 million were classified as obese. Overweight and obese patients are at increased risk of developing a host of cardiometabolic diseases and certain cancers, which subsequently increases...

Highlights from the 2017 APA Annual Meeting
June 8, 2017

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.

September News and New Research
September 1, 2014

SSRI discontinuation before pregnancy does not reduce risk of miscarriage, US FDA approves Contrave for weight management, maternal immune activation and increased risk for schizophrenia in offspring, and other news.

Continue reading (Members only)

Top of Page